Under 10% of people who could benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it publishes its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer access to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 without intervention.
"The latest guidelines recognises that excess weight is a long-term condition that can be managed with comprehensive and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major hurdles to broad availability to the treatments that can aid individuals in losing significant body mass, says the body.
GLP-1 Therapy Shortage
Even under the present most favorable scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization.
The advice encourages governments and firms to expand access, through strategies like licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is due to expire in a number of nations in 2026.
How Weight-Loss Jabs Work
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so people consume fewer calories.
Patients typically start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to people may see weight return within a year of stopping the treatment, when their usual hunger return.
Being carrying excess weight raises your chance for experiencing health problems, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts individuals in every country and was responsible for millions of fatalities worldwide in 2024, as per the health agency.
